PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic ...
PureTech Health plc (NASDAQ: PRTC) is a hub-and-spoke biotherapeutics company dedicated to changing how devastating diseases are treated. The company’s strategy is to build and invest in a portfolio of biotherapeutic programs and platforms while also creating (and, in many cases, partially spinning out) specialized “founded entities” that can pursue ...PureTech Health plc (NASDAQ: PRTC) is a hub-and-spoke biotherapeutics company dedicated to changing how devastating diseases are treated. The company’s strategy is to build and invest in a portfolio of biotherapeutic programs and platforms while also creating (and, in many cases, partially spinning out) specialized “founded entities” that can pursue their own clinical development paths, financing needs, and operational execution.
Business model and operations: PureTech’s reporting description highlights multiple operational segments: (1) an Internal segment focused on its own programs (including immunological, fibrotic, and lymphatic system mechanisms); (2) a Controlled Founded Entities segment made up of consolidated subsidiaries where the group either has or plans to hire independent management teams and those entities have raised—or are in the process of raising—third-party dilutive capital; (3) a Non-Controlled Founded Entities segment for companies where PureTech no longer holds majority voting control or board majority election rights; and (4) a Parent Company and Other segment that includes corporate support and certain R&D support functions not directly tied to a specific strategic segment, plus elimination of intercompany transactions. This structure allows PureTech to spread scientific and development risk across a network while maintaining a central innovation and capital-allocation function.
Products and pipeline approach: As a biotherapeutics company, PureTech’s “products” are primarily development-stage medicines and platform-enabled programs rather than mass-market products. Its public company materials describe it as developing medicines for areas such as intractable cancers and neurological/neuropsychological disorders, along with inflammatory, fibrotic, and immunological conditions and certain lymphatic and gastrointestinal diseases. The company also emphasizes launching and advancing therapeutics through its founded-entity ecosystem (e.g., announcements around new therapeutic companies and disease-area focus).
Cost, BOM, and financial perspective: Like many biotherapeutics firms, PureTech’s cost structure is heavily weighted toward R&D and clinical development activities (preclinical/clinical labor, lab and manufacturing-related external services, regulatory work, and scientific/clinical operations). While “BOM” is not a typical manufacturing term for drug discovery companies, the practical analogue is the composition of external and internal development inputs—specialized assays, trial sites/clinical operations, contract development and manufacturing (CDMO) engagements, compliance/regulatory expenses, and other consumables and service contracts. The provided financial metrics indicate a period of profitability pressure typical for pre-commercial biotech: margins and cash-flow-based metrics can be negative due to ongoing investment in development and operating costs.
Key people and leadership: The CEO is Robert William Henry Lyne. Source materials also list other senior leadership/co-founder involvement, including Eric Elenko (PhD) as co-founder and President, and finance/accounting leadership such as Michael Inbar (CPA, MBA) as Chief Accounting Officer.
Wishes/strategic intent: PureTech’s overall intent is to “transform innovation into value” by (a) improving the odds that differentiated science results in clinical impact, and (b) scaling the creation and support of founded entities that can attract capital and execute targeted development programs. Through its internal and founded-entity structure, the company aims to balance control of core innovation with the operational flexibility and specialized focus of independently managed therapeutic ventures.
Headquartered in Boston, Massachusetts, PureTech has been publicly traded since 2020-11-16 (as an IPO date shown in the provided overview), aligning with its transition to a public platform for funding and portfolio development.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$4.7M
-3.5%
+51.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-109.7M
-305.1%
-45.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+100.0%
+284.1%
+103.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-2114.7%
+25.0%
+30.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-2355.4%
-312.5%
+3.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-85.3M
+36.5%
+17.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-1831.6%
+34.2%
+45.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
6.3%
+16.4%
+11.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
6.59x
-29.4%
-22.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Greetings, and welcome to the PureTech Health 2025 Annual Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Allison Mead Talbot, Senior Vice President of Communications. Thank you, Allison. You may begin.
Allison Talbot: Thank you, everyone, for joining us for PureTech's 2026 Annual Results Webcast. Our annual report will be made available later today, portions of which are also filed with our Form 20-F. This information is available on the Investors page of our website at puretechhealth.com. I would like to remind you that during today's call, we will be making certain forward-looking statements. These statements are subject to various risks, uncertainties and assumptions that could cause our actual results to differ materially, and we ask that you refer to our annual report and our SEC filings for a complete discussion of these items. We undertake no obligation to revise or update any forward-looking statements or information, except as required by law. I also want to remind you that we will be referring to certain non-IFRS measures in this presentation. The presentation of this non-IFRS financial information is not intended to be considered in iCeleation or as a substitute for financial information presented in accordance with IFRS. A reconciliation of the IFRS to non-IFRS measures that we will be referring to today can be found in this presentation and is also available on our Investor Relations website at investors.puretechhealth.com and in our SEC filings. I'm joined today by members of our senior management team: Robert Lyne, Chief Executive Officer; Eric Elenko, Co-Founder and President; Chip Sherwood, General Counsel; Michael Inbar, Chief Accounting Officer; as well as Sven Dethlefs, CEO of our founded entity, Celea Therapeutics. Rob and Eric will discuss our strategic vision and path to value creation, including updates across our portfolio and our differentiated innovation engine. They will also provide a deep dive into the Gallop program, review our financial highlights and outline our anticipated catalysts for the remainder of the year. With that, I will now turn the call over to Rob, our Chief Executive Officer.
Robert Lyne: Thank you, Allison. Welcome, everyone, and thank you for joining us today. We are at a pivotal moment in the company's trajectory. Having announced our near-term operational focus in December, I'm pleased today to walk you through our refined strategy and portfolio progress. This next phase of our evolution is designed to translate our proven innovation model into greater shareholder value. As a reminder, PureTech is a Boston-based LSE-listed biotherapeutics company operating a hub-and-spoke model with a proven clinical and financial track record. Programs originate within the PureTech hub based on a thesis of targeting molecules with validated pharmacology and are then advanced through early clinical and …
